Showing results (91-100 of 100) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Signal Transduction and Targeted Therapy|February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trialDan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Jie Huang, Tao Wang, et al.Cancer Communications (London, England)|February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II studyJing Zheng, Tao Wang, Yunpeng Yang, et al.The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2026
Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trialJie Huang, Gang Chen, Zhehai Wang, et al.Nature Medicine|January 6, 2025
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.Lung Cancer (Amsterdam, Netherlands)|August 1, 2024
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trialShun Lu, Yiping Zhang, Guojun Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2022
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lu, Yiping Zhang, Guojun Zhang, et al.European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.Pageof 10